全文获取类型
| 收费全文 | 9246篇 |
| 免费 | 576篇 |
| 国内免费 | 38篇 |
专业分类
| 耳鼻咽喉 | 75篇 |
| 儿科学 | 303篇 |
| 妇产科学 | 198篇 |
| 基础医学 | 1444篇 |
| 口腔科学 | 210篇 |
| 临床医学 | 812篇 |
| 内科学 | 1825篇 |
| 皮肤病学 | 272篇 |
| 神经病学 | 1051篇 |
| 特种医学 | 207篇 |
| 外国民族医学 | 2篇 |
| 外科学 | 892篇 |
| 综合类 | 73篇 |
| 一般理论 | 12篇 |
| 预防医学 | 679篇 |
| 眼科学 | 193篇 |
| 药学 | 880篇 |
| 中国医学 | 11篇 |
| 肿瘤学 | 721篇 |
出版年
| 2023年 | 59篇 |
| 2022年 | 46篇 |
| 2021年 | 301篇 |
| 2020年 | 211篇 |
| 2019年 | 230篇 |
| 2018年 | 304篇 |
| 2017年 | 208篇 |
| 2016年 | 296篇 |
| 2015年 | 299篇 |
| 2014年 | 343篇 |
| 2013年 | 493篇 |
| 2012年 | 744篇 |
| 2011年 | 721篇 |
| 2010年 | 385篇 |
| 2009年 | 328篇 |
| 2008年 | 553篇 |
| 2007年 | 600篇 |
| 2006年 | 554篇 |
| 2005年 | 522篇 |
| 2004年 | 538篇 |
| 2003年 | 450篇 |
| 2002年 | 429篇 |
| 2001年 | 101篇 |
| 2000年 | 89篇 |
| 1999年 | 85篇 |
| 1998年 | 49篇 |
| 1997年 | 66篇 |
| 1996年 | 46篇 |
| 1995年 | 39篇 |
| 1994年 | 36篇 |
| 1993年 | 33篇 |
| 1992年 | 44篇 |
| 1991年 | 46篇 |
| 1990年 | 40篇 |
| 1989年 | 41篇 |
| 1988年 | 34篇 |
| 1987年 | 27篇 |
| 1986年 | 29篇 |
| 1985年 | 28篇 |
| 1984年 | 18篇 |
| 1983年 | 29篇 |
| 1982年 | 18篇 |
| 1981年 | 16篇 |
| 1977年 | 21篇 |
| 1976年 | 17篇 |
| 1975年 | 17篇 |
| 1974年 | 21篇 |
| 1973年 | 18篇 |
| 1971年 | 21篇 |
| 1970年 | 21篇 |
排序方式： 共有9860条查询结果，搜索用时 140 毫秒
1.
Paul G. Richardson Fredrik Schjesvold Katja Weisel Philippe Moreau Larry D. Anderson Darrell White Paula Rodriguez-Otero Pieter Sonneveld Monika Engelhardt Matthew Jenner Alessandro Corso Jan Dürig Michel Pavic Morten Salomo Meral Beksac Albert Oriol Jindriska Lindsay Anna Marina Liberati Monica Galli Pawel Robak Alessandra Larocca Munci Yagci Filiz Vural Abraham S. Kanate Ruiyun Jiang Lara Grote Teresa Peluso Meletios Dimopoulos 《European journal of haematology》2022,108(1):73-83
2.
Milena Peruhova Monika Peshevska-Sekulovska Tsvetelina Velikova 《World Journal of Immunology》2021,11(2):11-16
In liver transplant patients, solid tumors and post-transplant lymphoproliferative disorders have emerged as significant long-term mortality causes. In addition, it is assumed that de novo malignancy after liver transplantation (LT) is the second-leading cause of death after cardiovascular complications. Well-established risk factors for post-transplant lymphoproliferative disorders and solid tumors are calcineurin inhibitors, tacrolimus, and cyclosporine, the cornerstones of all immunosuppressive therapies used after LT. The loss of immunocompetence facilitated by the host immune system due to prolonged immunosuppressive therapy leads to cancer development, including LT patients. Furthermore, various mechanisms such as bacterial dysbiosis, activation through microbe-associated molecular patterns, leaky gut, and bacterial metabolites can drive cancer-promoting liver inflammation, fibrosis, and genotoxicity. Therefore, changes in human microbiota composition may contribute further to de novo carcinogenesis associated with the severe immunosuppression after LT. 相似文献
3.
George Haddad Malte Klling Urs A. Wegmann Angela Dettling Harald Seeger Roland Schmitt Inga Soerensen-Zender Hermann Haller Andreas D. Kistler Anne Dueck Stefan Engelhardt Thomas Thum Thomas F. Mueller Rudolf P. Wüthrich Johan M. Lorenzen 《Journal of the American Society of Nephrology : JASN》2021,32(2):323
4.
5.
Joshua Demb Esther K. Wei Monika Izano Stephen Kritchevsky Helen Swede Anne B. Newman Michael Shlipak Tomi Akinyemiju Steven Gregorich Dejana Braithwaite 《Journal of Geriatric Oncology》2019,10(2):265-271
Objectives
We examined the association between three inflammatory markers (Interleukin (IL)-6, C-reactive protein (CRP), tumor necrosis factor (TNF)-α) and incident lung cancer using baseline, updated, and averaged inflammatory measures in older adults.Methods
We fitted multivariable Cox models to assess whether circulating levels of inflammation markers were associated with incident lung cancers in the Health Aging, Body and Composition (HealthABC) prospective cohort of 3075 older adults aged 70–79?years at baseline. IL-6 and CRP were measured biennially, whereas TNF-α was measured at baseline.Results
Baseline levels of IL-6 were significantly associated with incident lung cancer risk in a model that adjusted for age, gender, race, and site (Model 1) (Hazard RatioT3 vs. T1: 3.34, 95% Confidence Interval: 1.91, 5.85) and in a model adjusted for health factors linked to chronic inflammation (Model 2) (HR T3 vs. T1: 2.57, 95% CI: 1.41, 4.65). The associations observed in time-updated IL-6 (HR T3 vs. T1: 2.47, 95% CI: 1.43, 4.28), cumulatively averaged IL-6 (HR T3 vs. T1: 2.47, 95% CI: 1.43, 4.35), and baseline CRP levels (HR T3 vs. T1: 1.85, 95% CI: 1.11, 3.08) with incident lung cancer in Model 1 were not statistically significant in Model 2.Conclusions
Baseline CRP and IL-6 levels were associated with increased risk of lung cancer in Model 1 and both models, respectively. Chronic IL-6 inflammation, as quantified by repeated measures was associated with incident lung cancer in Model 1, but not Model 2. Further research is needed to understand the role of CRP and IL-6 in lung carcinogenesis. 相似文献6.
7.
8.
9.
10.